Actively Recruiting
Evaluating Safety, Tolerability, and Pharmacokinetics of Oral Emraclidine in Healthy Elderly Adults Aged 65-85
Led by AbbVie · Updated on 2026-09-15
52
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the drug emraclidine moves through the body and its safety in healthy elderly adults aged 65 to 85 years. This Phase 1, randomized, placebo-controlled study aims to understand the drugs pharmacokinetics, tolerability, and any adverse events in this population. The trial is sponsored by AbbVie and focuses on basic science to gather important information about the drugs effects. Participants will receive oral doses of either emraclidine or a placebo for either 10 days or 17 days, depending on their assigned group. The study uses a sequential design with multiple groups receiving ascending oral doses to assess safety and how the drug is processed in the body. The intervention involves taking oral tablets while the research team monitors participants closely. During the study, participants will undergo various assessments including vital sign measurements, electrocardiograms ECGs, physical examinations, and laboratory tests. Researchers will track changes in safety scales such as the Columbia-Suicide Severity Rating Scale and movement disorder rating scales up to approximately 20 days. Blood samples will be collected to measure drug concentration and metabolism. The total observation period for adverse events may extend up to about 50 days, ensuring thorough safety monitoring.
CONDITIONS
Brief Title
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here